Compare Tilray Brands Inc (TLRY) vs DENTSPLY SIRONA Inc (XRAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tilray Brands Inc vs DENTSPLY SIRONA Inc — how do they compare? Tilray Brands Inc trades at $4.21 (market cap $577.15M), while DENTSPLY SIRONA Inc trades at $10.7 (market cap $2.14B). The key difference: DENTSPLY SIRONA Inc is far larger — about 3.7× Tilray Brands Inc's market cap, and DENTSPLY SIRONA Inc pays a 5.04% dividend while Tilray Brands Inc pays none. Which is the better fit depends on your goals.
| TLRY | XRAY | |
|---|---|---|
Market Cap | $577.15M | $2.14B |
Sector | Health | Health |
52-Week High | $21.00 | $14.68 |
52-Week Low | $3.88 | $9.64 |
Enterprise Value | $744.29M | $4.21B |
Dividend Yield | — | 5.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TLRY trades at $4.30, down 4.44% today, reflecting ongoing investor skepticism despite record fiscal 2026 revenue of $915 million. The stock shows bearish technical signals with key support at $4.00, while fundamentals reveal significant challenges including negative net income margins (-13.26%) and consecutive earnings misses. Recent developments include strategic partnerships expansion in New York and California spirits markets and increased medical cannabis production capacity to 275 metric tonnes.
TLRY faces substantial execution risks with persistent losses and negative cash flow, though trading below book value (P/B 0.37) offers potential value. Analyst consensus remains cautious with 65% hold ratings, while regulatory progress in cannabis remains a key catalyst. The stock requires successful margin improvement and U.S. regulatory clarity for sustained recovery.
XRAY trades at $10.99, down 3.43% on the day, reflecting ongoing pressure from declining revenues and negative profitability. The stock shows a bearish technical signal, with key support at $10. Recent Q2 2026 earnings beat estimates but sales fell 4.1%, highlighting persistent challenges in dental markets. Cash flow improved in 2025, yet net losses and high debt levels remain concerns.
The outlook is cautious; while analyst consensus suggests modest upside to a $12.50 target, weak margins, falling sales, and potential fiduciary scrutiny pose significant risks. Recovery depends on successful execution of the company's turnaround plan amid competitive and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Tilray Brands Inc
Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →About DENTSPLY SIRONA Inc
Dentsply Sirona Inc is a global manufacturer and distributor of dental supplies and equipment. The company's operating segments include Technologies & Equipment, which is responsible for the design, manufacture, sales, and distribution of products including dental implants, CAD/CAM systems, orthodontic clear aligner products, imaging systems, treatment centers, instruments, as well as certain healthcare device products, primarily catheters
Read more on XRAY →
